Traumatology Department, University of Szeged, Semmelweis u. 6, Szeged, 6725, Hungary.
Clinical Pharmacy Department, University of Szeged, Szikra utca 8, Szeged, 6725, Hungary.
J Orthop Surg Res. 2020 Sep 15;15(1):414. doi: 10.1186/s13018-020-01941-x.
BACKGROUND: Atypical femoral fracture is one of the many complications after the long-term use of bisphosphonates. The American Society for Bone and Mineral Research has officially excluded periprosthetic femoral fractures (PFFs) from the definition of atypical femoral fractures (AFFs). Several case reports found that PFFs can occur with characteristics similar to those of AFFs. The purpose of our study was to evaluate the proportion of atypical fractures among Vancouver type B1 fractures, and to determine the association between the long-term use of bisphosphonates and the occurrence of atypical periprosthetic femoral fractures (APFFs). METHODS: In this retrospective study, we reviewed 41 patients with Vancouver type B1 periprosthetic fractures between January 1, 2011 and December 31, 2018. We classified them into two groups, namely atypical and typical PFFs, based on the fracture morphology. We noted the proportion of atypical periprosthetic fractures among B1 fractures and identified risk factors. RESULTS: Among the 41 PFFs, 5 (13%) fractures were classified as atypical PFF based on the radiological characteristics. The longer duration of bisphosphonate use was probably the only independent risk factor that significantly increases the occurrence of APFF (p = 0.03, 0.08 (CI 0.008 - 0.16)). There were no significant differences in age, gender, body mass index, comorbidities, corticosteroid use, positioning of the femoral stem, the method of fixation (cemented or cementless) and time lapse from before the primary prosthesis implantation to the PFF in the development of atypical fracture type. CONCLUSIONS: There seems to be a correlation between the long-term intake of bisphosphonates and the atypical periprosthetic fracture. Atypical femoral fracture can also occur in the periprosthetic form. TRIAL REGISTRATION: Study number: 22/2019-SZTE, http://www.klinikaikutatas.hu/hu/kutatasetika/jovahagyott-vizsgalatok-koezerdeku-adatai/category/25-jovahagyott-vizsgalatok-kozerdeku-adatai-rkeb-2019.html?download=985:22-2019 .
背景:非典型股骨骨折是长期使用双膦酸盐后的众多并发症之一。美国骨骼与矿物质研究学会已正式将假体周围股骨骨折(PFFs)排除在非典型股骨骨折(AFFs)的定义之外。有几项病例报告发现,PFFs 可能具有与 AFFs 相似的特征。我们的研究目的是评估温哥华 B1 型骨折中非典型骨折的比例,并确定长期使用双膦酸盐与非典型假体周围股骨骨折(APFFs)的发生之间的关联。
方法:在这项回顾性研究中,我们回顾了 2011 年 1 月 1 日至 2018 年 12 月 31 日期间 41 例温哥华 B1 型假体周围骨折患者。我们根据骨折形态将他们分为两组,即非典型和典型 PFFs。我们记录了 B1 型骨折中非典型假体周围骨折的比例,并确定了危险因素。
结果:在 41 例 PFFs 中,根据影像学特征,有 5 例(13%)骨折被归类为非典型 PFF。双膦酸盐使用时间较长可能是唯一显著增加 APFF 发生的独立危险因素(p=0.03,0.08(CI 0.008-0.16))。在非典型骨折类型的发展过程中,年龄、性别、体重指数、合并症、皮质类固醇使用、股骨柄位置、固定方法(骨水泥或非骨水泥)以及从初次假体植入到 PFF 的时间间隔方面,两组之间没有显著差异。
结论:长期服用双膦酸盐与非典型假体周围骨折之间似乎存在关联。假体周围也可能发生非典型股骨骨折。
试验注册:研究编号:22/2019-SZTE,http://www.klinikaikutatas.hu/hu/kutatasetika/jovahagyott-vizsgalatok-koezerdeku-adatai/category/25-jovahagyott-vizsgalatok-kozerdeku-adatai-rkeb-2019.html?download=985:22-2019。
J Orthop Surg Res. 2020-9-15
J Bone Miner Res. 2018-10-2
J Orthop Surg (Hong Kong). 2016-8
Osteoporos Int. 2023-6
Geriatr Orthop Surg Rehabil. 2022-4-11
Br J Clin Pharmacol. 2019-2-28
J Bone Miner Res. 2018-10-2
J Am Acad Orthop Surg. 2018-12-15
J Bone Miner Res. 2018-5-24